Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme. Together they halt parasite energy production and folate synthesis, leading to synergistic parasite death.

The exact dosing regimen is determined by the prescribing clinician based on the indication, patient weight, age, and travel schedule. Typical regimens involve one tablet taken orally once daily, but the prescriber sets the precise dose and duration.

Safety data for Malarone during pregnancy are limited, and it is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the risk. The drug is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before use.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Malarone combines two agents with complementary mechanisms, offering a high efficacy rate and a favorable safety profile compared with monotherapy options such as chloroquine or mefloquine. Its once‑daily dosing and tolerability make it a preferred choice for many travelers, though drug‑resistance patterns and individual contraindications must be considered.

Store Malarone tablets at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not store in humid or excessively hot environments.

Malarone tablets are taken orally with food or a milky drink to enhance absorption. The tablet should be swallowed whole with a full glass of water. Patients should follow the prescriber’s instructions regarding timing relative to travel and treatment courses.

Serious adverse reactions, although rare, include severe hypersensitivity reactions such as anaphylaxis, hepatotoxicity manifested by elevated liver enzymes or jaundice, and hemolytic anemia, particularly in individuals with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency.

Malarone is contraindicated in patients with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, G6PD deficiency, pregnant or breastfeeding women unless the benefit outweighs the risk, and those taking medications that have major interactions.